Swiss regulatory aspects and evaluation considerations for ATMPs and other nucleic acid-based products such as mRNA-based vaccines

"Swissmedic is taking various measures to respond to innovation in order to provide appropriate support for developers and meet the expectations of industry and patient...”

Please enter your email to access content Read now